Boehringer Ingelheim USA Corporation

Roche announced a definitive merger agreement to acquire 89bio for $14.50 per share in cash plus contingent value rights, totaling up to $3.5 billion.

The Unified Patent Court's Court of Appeal granted its first preliminary injunction in the pharmaceutical sector, blocking Zentiva from launching generic versions of Boehringer Ingelheim's Ofev across 17 European territories.

The FDA has accepted Echosens' Letter of Intent to qualify liver stiffness measurement by FibroScan® as the first non-invasive surrogate endpoint for MASH clinical trials.

The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.

Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.

Boehringer Ingelheim has signed a contract development and manufacturing agreement with AnGes for the drug substance of their investigational hepatocyte growth factor gene therapy targeting peripheral arterial disease.

Molecular Partners has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer effective October 1, 2025, bringing extensive oncology drug development experience from senior roles at Roche, MorphoSys, Boehringer Ingelberg, and SOTIO Biotech.

The FDA granted accelerated approval to HERNEXEOS (zongertinib) in August 2025, marking the first oral therapy specifically targeting HER2 tyrosine kinase domain mutations in non-squamous NSCLC.

Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration to develop extended-release ophthalmic therapies using Re-Vana's drug delivery technology that releases treatments over 6-12 months.

Avalyn Pharma secured $100 million in an oversubscribed Series D financing round to advance inhaled formulations of existing pulmonary fibrosis drugs pirfenidone and nintedanib.